Literature DB >> 18430616

A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma.

Mary C Long1, Chantelle Bennetto-Hood, Edward P Acosta.   

Abstract

This work describes an assay system that has been developed to quantify raltegravir concentrations in human plasma using a liquid-liquid extraction technique paired with HPLC separation and MS-MS detection. The dynamic range of this assay extends from 1 to 3000 ng/mL, with a coefficient of determination (r(2), mean+/-SD) of 0.9992+/-0.0002. The mean precision values for calibration standards ranged from 0.6% to 3.0%, while accuracy values were 96.5-104.3%. This procedure is an accurate, precise, and sensitive method for raltegravir quantitation and was successfully validated using external proficiency testing.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18430616     DOI： 10.1016/j.jchromb.2008.03.022

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN： 1570-0232            Impact factor:   3.205


  14 in total

1.  Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of age.

Authors:  Matthew L Rizk; Lihong Du; Chantelle Bennetto-Hood; Larissa Wenning; Hedy Teppler; Brenda Homony; Bobbie Graham; Carrie Fry; Sharon Nachman; Andrew Wiznia; Carol Worrell; Betsy Smith; Edward P Acosta
Journal:  J Clin Pharmacol       Date:  2015-04-13       Impact factor: 3.126

2.  Simultaneous measurement of etravirine, maraviroc and raltegravir in pigtail macaque plasma, vaginal secretions and vaginal tissue using a LC-MS/MS assay.

Authors:  Anna K Blakney; Yonghou Jiang; Dale Whittington; Kim A Woodrow
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-05-02       Impact factor: 3.205

3.  Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.

Authors:  D McMahon; J Jones; A Wiegand; S J Gange; M Kearney; S Palmer; S McNulty; J A Metcalf; E Acosta; C Rehm; J M Coffin; J W Mellors; F Maldarelli
Journal:  Clin Infect Dis       Date:  2010-03-15       Impact factor: 9.079

4.  An accurate and precise high-performance liquid chromatography method for the rapid quantification of the novel HIV integrase inhibitor raltegravir in human blood plasma after solid phase extraction.

Authors:  Naser L Rezk; Nicole White; Angela D M Kashuba
Journal:  Anal Chim Acta       Date:  2008-09-11       Impact factor: 6.558

5.  Raltegravir pharmacokinetics in neonates following maternal dosing.

Authors:  Diana F Clarke; Edward P Acosta; Matthew L Rizk; Yvonne J Bryson; Stephen A Spector; Lynne M Mofenson; Edward Handelsman; Hedy Teppler; Carolee Welebob; Deborah Persaud; Mae P Cababasay; JiaJia Wang; Mark Mirochnick
Journal:  J Acquir Immune Defic Syndr       Date:  2014-11-01       Impact factor: 3.731

6.  Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.

Authors:  Sharon Nachman; Nan Zheng; Edward P Acosta; Hedy Teppler; Brenda Homony; Bobbie Graham; Terence Fenton; Xia Xu; Larissa Wenning; Stephen A Spector; Lisa M Frenkel; Carmelita Alvero; Carol Worrell; Edward Handelsman; Andrew Wiznia
Journal:  Clin Infect Dis       Date:  2013-10-21       Impact factor: 9.079

7.  Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110.

Authors:  Diana F Clarke; Mark Mirochnick; Edward P Acosta; Edmund Capparelli; Anne Chain; Hedy Teppler; Betsy Smith; Jos Lommerse
Journal:  J Acquir Immune Defic Syndr       Date:  2019-12-01       Impact factor: 3.731

8.  Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age.

Authors:  Sharon Nachman; Carmelita Alvero; Edward P Acosta; Hedy Teppler; Brenda Homony; Bobbie Graham; Terence Fenton; Xia Xu; Matthew L Rizk; Stephen A Spector; Lisa M Frenkel; Carol Worrell; Edward Handelsman; Andrew Wiznia
Journal:  J Pediatric Infect Dis Soc       Date:  2015-02-07       Impact factor: 3.164

9.  Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110).

Authors:  Diana F Clarke; Edward P Acosta; Mae Cababasay; Jiajia Wang; Anne Chain; Hedy Teppler; Stephanie Popson; Bobbie Graham; Betsy Smith; Rohan Hazra; Kat Calabrese; Yvonne Bryson; Stephen A Spector; Jos Lommerse; Mark Mirochnick
Journal:  J Acquir Immune Defic Syndr       Date:  2020-05-01       Impact factor: 3.771

10.  Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097.

Authors:  Diana F Clarke; Jos Lommerse; Edward P Acosta; Mae P Cababasay; Jiajia Wang; Stephen A Spector; Anne Chain; Elizabeth Smith; Hedy Teppler; Rohan Hazra; Kat Calabrese; Bobbie Graham; Stephanie Popson; Yvonne Bryson; Mark Mirochnick
Journal:  J Acquir Immune Defic Syndr       Date:  2020-12-15       Impact factor: 3.771
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.